This result indicates that in addition to acting via an apoptosis-promoting pathway, celecoxib may achieve antitumor effects by reducing the expression of the cancer stem cell markers HIF-2α, Oct-4 and ABCG2. The gene discussed is EPAS1; the disease is cancer.